drugset
drugset / Trial / NCT03808298

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

NCT03808298 ↗

Phase 1 Completed 57 enrolled Hoffmann-La Roche
RandomizedCrossoverTriple-blindTreatment

Summary

This was a single-center, multiple-dose, randomized, double-blind, placebo-controlled, positive-controlled, twelve sequence, 3-period cross-over study to investigate the effect of balovaptan on the QTc interval in healthy subjects.

Timeline

Start
2019-02-07
Primary completion
2019-06-14
Completion
2019-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Balovaptan Small molecule — Oral
Subject Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.